Type 1 diabetes

Investors are closely watching stock trades by members of Congress, where committee roles and trade timing can raise red flags—or attract copycats. That scrutiny has intensified after one lawmaker disclosed purchases in a microcap company valued at less than $5 million, an unusually small and risky...

The FDA has cleared Insulet Corporation's (NASDAQ: PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for patients aged six years of age and older with type 1 diabetes. Omnipod 5 is the first tubeless automated insulin delivery system integrated with the Dexcom G6...

Provention Bio Inc (NASDAQ: PRVB) said that it had resolved the comparability concerns with the FDA, and teplizumab is clear for resubmission.  The resubmission should be ready to go in Q1 of FY22. After discussions with the FDA, Provention agreed to use pharmacokinetic modeling to...

On 25 October 2021, the marketing authorization holder for dapagliflozin withdrew the indication for type 1 diabetes across Europe and the U.K. The SGLT2 inhibitor dapagliflozin has been indicated for the treatment of type 2 diabetes since 2012.  AstraZeneca Plc's (NASDAQ:...

When it comes to treating chronic, immune-mediated diseases, the standard course is to wait for symptoms before beginning treatment. But by that point, it may be too late for intervention. These diseases can silently do irreversible damage, according to Provention Bio Inc (NASDAQ: PRVB) CEO...